Oncimmune is an industry leader in early cancer detection. The company has pioneered the development of autoantibody assay technologies that have the potential to allow earlier cancer detection than other methods and can be applied to a very wide range of solid tumour types. The Company's proprietary EarlyCDT technology platform was launched in 2009 and EarlyCDT-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT tests for liver and ovarian cancer are in final validation.
Oncimmune is headquartered in Nottingham, United Kingdom with testing facilities in the US.